Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2016


#909196

77pages

Global Markets Direct

$ 3500

In Stock

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2016, provides in depth analysis on Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted pipeline therapeutics.

The report provides comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)
- The report reviews Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) Overview 8
Therapeutics Development 9
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Products under Development by Stage of Development 9
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Products under Development by Therapy Area 10
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Products under Development by Indication 11
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Products under Development by Companies 15
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Products under Development by Universities/Institutes 19
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Therapeutics Assessment 21
Assessment by Monotherapy/Combination Products 21
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Companies Involved in Therapeutics Development 27
Boehringer Ingelheim GmbH 27
Celldex Therapeutics Inc 28
GlaxoSmithKline Plc 30
Immune Design Corp 31
ImmunoFrontier Inc 32
Kite Pharma Inc 33
Sanofi Pasteur SA 34
Scancell Holdings Plc 35
Vault Pharma Inc 36
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drug Profiles 37
BI-1361849 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CDX-1401 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Cellular Immunotherapy to Inhibit NY ESO-1 for Oncology - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CMB-305 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
CYN-101 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
G-305 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
GSK-2241658A - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
IMF-001 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
IMM-65 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
LV-305 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
SCIB-2 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
VCP-2292 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
VPI-111 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Dormant Projects 60
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Discontinued Products 63
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Featured News & Press Releases 64
Oct 10, 2016: Scancell preparing SCIB2 for clinical study in lung cancer 64
Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate LV305 at ASCO 64
Jun 08, 2016: Immune Design Announces Updated Results For Immuno-oncology Product Candidate CMB305 At ASCO 65
Jun 04, 2016: Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma 66
Apr 21, 2016: Immune Design Announces Presentation on LV-305 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 67
Apr 18, 2016: Celldex Therapeutics Presents Poster on CDX-1401 at the AACR Annual Meeting 2016 67
Feb 09, 2016: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trial of CMB305 68
Jan 08, 2016: Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305 69
Nov 11, 2015: Immune Design Announces Start of Randomized Phase 2 Cancer Immunotherapy Combination Trial in Patients With Soft Tissue Sarcoma 69
Aug 12, 2015: Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration 70
May 13, 2015: Immune Design Announces Positive Data from Phase 1 Studies On LV305 at the 2015 American Society of Clinical Oncology Annual Meeting 70
May 13, 2015: Immune Design To Present Positive Phase 1 Data From On G305 at the 2015 American Society of Clinical Oncology Annual Meeting 72
Mar 31, 2015: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trials of Immuno-Oncology CMB305 Agent 73
Mar 26, 2015: Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent 74
Jun 05, 2014: Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of LV305 Immuno-Oncology Agent 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables
Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Products under Development by Companies, H2 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Assessment by Monotherapy/Combination Products, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Pipeline by Boehringer Ingelheim GmbH, H2 2016 27
Pipeline by Celldex Therapeutics Inc, H2 2016 28
Pipeline by GlaxoSmithKline Plc, H2 2016 30
Pipeline by Immune Design Corp, H2 2016 31
Pipeline by ImmunoFrontier Inc, H2 2016 32
Pipeline by Kite Pharma Inc, H2 2016 33
Pipeline by Sanofi Pasteur SA, H2 2016 34
Pipeline by Scancell Holdings Plc, H2 2016 35
Pipeline by Vault Pharma Inc, H2 2016 36
Dormant Projects, H2 2016 60
Dormant Projects (Contd..1), H2 2016 61
Dormant Projects (Contd..2), H2 2016 62
Discontinued Products, H2 2016 63

List of Figures
Number of Products under Development for, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Routes of Administration, H2 2016 23
Number of Products by Stage and Routes of Administration, H2 2016 23
Number of Products by Molecule Types, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 25